BioSpace News Archive

Better Collaboration: 7 Tips for Effective Workplace Communication

By effectively communicating with colleagues, you can improve collaboration as well as your own work experience. It all starts with active listening.

June 18, 2024
·
4 min read
·
Angela Gabriel
Decheng Capital Eyes $700M Raise for Fifth Life Sciences Fund as VC Heats Up

On the heels of last week’s announcements from Foresite Capital and J.P. Morgan Private Capital, Decheng is planning to raise $700 million for its fifth life sciences fund.

June 18, 2024
·
2 min read
·
Tristan Manalac
FDA

Merck Wins FDA Approval for First Pneumococcal Vaccine Designed for Adults

Merck on Monday secured the FDA’s green light for its 21-valent pneumococcal vaccine Capvaxive, which covers serotypes responsible for around 84% of invasive pneumococcal disease cases.

June 18, 2024
·
2 min read
·
Tristan Manalac
Policy

Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies After Patient Deaths

Following two deaths due to presumed sepsis, the FDA has placed a partial clinical hold on three trials for Zentalis’ azenosertib including a Phase I in solid tumors, Phase II in platinum-resistant ovarian cancer and Phase II in uterine serous carcinoma.

June 18, 2024
·
1 min read
·
Kate Goodwin
FDA

FDA Action Alert: Merck, Verona, AbbVie and Rocket

The FDA is facing four big target action dates in the final week of June, including one label expansion for a bispecific antibody and another for an investigational gene therapy.

June 18, 2024
·
4 min read
·
Tristan Manalac
Business

Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies

Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.

June 18, 2024
·
2 min read
·
Tyler Patchen
Drug Development

GSK Reignites Blenrep Blockbuster Aspirations With Data from Phase III Studies

Promising data from the DREAMM-7 and DREAMM-8 trials have revitalized GSK’s blockbuster goals for its antibody-drug conjugate Blenrep, positioned as a second-line treatment for multiple myeloma.

June 18, 2024
·
2 min read
·
Tristan Manalac
BIOSECURE’s Surprise Absence, the $100+ Billion Future Weight-Loss Market, DIA and More

This week’s news ranged from BioSpace’s on-the-ground updates from DIA to safety concerns in clinical trials to BIOSECURE Act updates to new projections that the GLP-1 market could top $100 billion within 10 years.

June 18, 2024
·
2 min read
Policy

5 FDA Decisions to Watch in the Second Half of 2024

The next six months for the FDA are primed to be as groundbreaking as the first six, with Eli Lilly’s donanemab and Lykos Therapeutics’ MDMA-assisted PTSD therapy on the docket, among others.

June 18, 2024
·
6 min read
·
Heather McKenzie
Drug Development

AstraZeneca’s Truqap Flops in Phase III Triple-Negative Breast Cancer Trial

Bucking its recent winning streak in oncology, AstraZeneca reported Tuesday that its AKT inhibitor Truqap failed to significantly boost overall survival in patients with triple-negative breast cancer.

June 18, 2024
·
2 min read
·
Tristan Manalac